U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

FDA News, New FDA Approvals
May 15, 2020
A+ A-
Email Print

Article Link: U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

PRINCETON, N.J.–(BUSINESS WIRE)–May 15, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Pomalyst ® (pomalidomide) was approved by the U.S. Food and Drug Administration (FDA) for patients with AIDS-related Kaposi sarcoma whose…

Source: FDA New Drug Approvals

Posted by

Newer Post
Older Post